ArticleMicrobial cell (Graz, Austria)2026
Prohibitins: emerging host targets of bacteria and viruses at the plasma membrane, mitochondria, and cytoplasm.
Article in Microbial cell (Graz, Austria), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Ubiquitously expressed Prohibitin-1 (PHB1) and Prohibitin-2 (PHB2) serve pleiotropic functions in cellular processes, including signal transduction, mitochondrial metabolism and dynamics, and lipid raft formation. Located in phospholipid-rich subcellular sites such as the plasma membrane and mitochondrial inner membrane, PHB1 and PHB2 are emerging as important host targets for bacteria and viruses, influencing infection and host responses by these microbes. Here, we present the current understanding of PHB1 and PHB2 in bacterial and viral infection based on the cellular localization of PHBs at the plasma membrane, mitochondria, and cytoplasm. We also discuss the potential of targeting PHBs as therapeutics for bacterial and viral infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.